Comparison of sleep quality before and after chemotherapy in locally advanced non-small-cell lung cancer patients: a prospective study and literature review

被引:0
|
作者
Nidhal, Belloumi [1 ]
Sonia, Maalej [2 ,3 ]
Imene, Bachouche [3 ]
Fatma, Chermiti [3 ]
Soraya, Fenniche [3 ]
机构
[1] Univ Tunis El Manar, Pavil Abderrahman Mami Hosp 4, Dept Pulmonol, Tunis, Tunisia
[2] Univ Tunis El Manar, Pavil D Abderrahman Mami Hosp, Dept Pulmonol, Ariana, Tunisia
[3] Univ Tunis El Manar, Fac Med Tunis, Ariana, Tunisia
来源
EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS | 2021年 / 70卷 / 04期
关键词
chemotherapy; depression; lung cancer; sleepuwake disturbance; OF-LIFE; BREAST-CANCER; DISTURBANCES; SYMPTOMS; THERAPY; FATIGUE; OUTPATIENTS; DEPRESSION; DIAGNOSIS; PATTERNS;
D O I
10.4103/ejcdt.ejcdt_221_19
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Outcome of sleep disturbances in lung cancer patients before and after treatment is not much reported. Their intensity and their correlation to quality of life or to humor disturbances were not widely studied. The aim of this study was to report precisely sleep disturbances in advanced stage lung cancer patients, their outcome after chemotherapy and/or radiotherapy, and their correlation to anxiodepressive humor. Patients and methods It was a prospective study including 64 patients with stage 3 or 4 non-small-cell lung cancer. Patients answered the Tunisian dialectal version of the following questionnaires: Pittsburgh sleep quality index and hospital anxiety depression scale in order to evaluate, respectively, the sleep quality and anxiodepressive troubles. The questionnaires took place before chemotherapy and then were repeated after chemotherapy was over. Results The mean age was 62.9 years. All patients were active smokers. Before chemotherapy, there were 10 (15%) patients with poor sleep quality. Most frequent complaints were daily sleepiness (70%) and nocturnal arousals (100%). Sixteen (25%) patients had depressive humor. Depression was statistically more frequent among patients with poor sleep quality (80 vs 15%, P<0.001). After chemotherapy, the mean Pittsburgh sleep quality index score increased from 2.9 to 5.4 and 45% of all patients had poor sleep quality. Most frequent complaints were extension of sleep latency (69%), daily sleepiness (98%), and nocturnal arousals (100%). After chemotherapy, depressive humor was reported in 34.3% of all patients, with higher prevalence among patients with poor sleep quality (58 vs 14%, P<0.001). Anxious humor was reported in 17% of all patients. A higher prevalence was correlated with poor sleep quality (31 vs 6%, P<0.001). The predicting factors of sleep disturbance according to statistical univariate analysis were delayed diagnosis confirmation (P=0.05), delayed start of treatment (P<0.001), and anxious (P=0.001) or depressive humor (P=0.001). Multivariate analysis confirmed the correlation of sleep disturbance to delayed diagnosis confirmation and treatment onset. Conclusion This study insisted on the persistence and potential intensity worsening of sleep disturbances in advanced stage non-small-cell lung cancer patients. The authors, hereby, reported a statistical correlation between sleep quality and humor quality in patients.
引用
收藏
页码:516 / 525
页数:10
相关论文
共 50 条
  • [31] Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer
    Marinopoulos, Spyridon
    Skorda, Lamprini
    Karatapanis, Stylianos
    Rasidakis, Antonis
    MEDICAL ONCOLOGY, 2008, 25 (04) : 415 - 418
  • [32] Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review
    Ellis, Peter M.
    Vella, Emily T.
    Ung, Yee C.
    CLINICAL LUNG CANCER, 2017, 18 (05) : 444 - U75
  • [33] Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer
    Oshita, F.
    Ohe, M.
    Honda, T.
    Murakami, S.
    Kondo, T.
    Saito, H.
    Noda, K.
    Yamashita, K.
    Nakayama, Y.
    Yamada, K.
    BRITISH JOURNAL OF CANCER, 2010, 103 (09) : 1325 - 1330
  • [34] Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
    Rossi, Antonio
    La Salvia, Anna
    Di Maio, Massimo
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (03) : 171 - 180
  • [35] Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice
    Jouveshomme, S
    Hermant, P
    Patte, D
    REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (04) : 719 - 726
  • [36] Chemotherapy of elderly patients with non-small-cell lung cancer
    Kloke, O
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2001, 34 (04): : 277 - 279
  • [37] The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer
    Tamburini, M
    Buccheri, G
    Brunelli, C
    Ferrigno, D
    SUPPORTIVE CARE IN CANCER, 2000, 8 (03) : 223 - 228
  • [38] Low Concentrations of Dehydroepiandrosterone Sulfate are Associated with Depression and Fatigue in Patients with Non-Small-Cell Lung Cancer After Chemotherapy
    Fang, Yu-Hung
    Hsieh, Meng-Jer
    Hung, Ming-Szu
    Lin, Yu-Ching
    Kuo, Liang-Tseng
    Lu, Mong-Liang
    Tzang, Bor-Show
    Chen, Vincent Chin-Hung
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 2103 - 2109
  • [39] Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients
    Randon, G.
    Galli, G.
    De Toma, A.
    Pagani, F.
    Trevisan, B.
    Signorelli, D.
    Proto, C.
    Prelaj, A.
    Ferrara, R.
    Ganzinelli, M.
    Pallavicini, L.
    Di Mauro, R.
    Zilembo, N.
    De Braud, F.
    Garassino, M.
    Lo Russo, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S416 - S416
  • [40] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Crawford, Jeffrey
    Denduluri, Neelima
    Patt, Debra
    Jiao, Xiaolong
    Morrow, Phuong Khanh
    Garcia, Jacob
    Barron, Richard
    Lyman, Gary H.
    SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 925 - 932